COMMUNIQUÉS West-GlobeNewswire

Merus to Report First Quarter 2017 Financial & Mid-Year Operating Results on July 11, 2017

07/07/2017 - 17:51

Conference call and webcast scheduled on 4:30pm ET UTRECHT, The Netherlands, July 06, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody [...]

Merus communiquera les résultats financiers du premier trimestre 2017 et les résultats d'exploitation de mi exercice le 11 juillet 2017

07/07/2017 - 17:51

Conférence téléphonique et diffusion sur le Web prévues à 16 h 30 HNE UTRECHT, Pays-Bas, le 6 juillet 2017 (GLOBE NEWSWIRE) - Merus N.V. (Nasdaq:MRUS), une société d'immuno-oncologie de stade clinique qui développe des [...]

MPI: Oncology Venture and Eisai Forge Exclusive Global License Agreement for Clinical Stage Oncology Drug PARP Inhibitor E7449 - 2X-121

07/07/2017 - 14:30

2X Oncology to conduct Phase 2 Study of 2X-121 in metastatic breast cancer patients Hoersholm, Denmark, and Cambridge, MA, July 7, 2017 - Oncology Venture AB ("Oncology Venture") and 2X Oncology Inc. ("2X Oncology"), [...]

DBV Technologies : Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social

07/07/2017 - 12:42

Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social (Article 223-16 du Règlement Général de l'Autorité des Marchés Financiers) Place de cotation : NYSE Euronext [...]

DBV Technologies : Monthly information regarding the total number of voting rights and total number of shares of the Company

07/07/2017 - 12:42

Monthly information regarding the total number of voting rights and total number of shares of the Company (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris [...]

Targovax ASA: Notification of trade by primary insiders

07/07/2017 - 11:16

Reference is made to the stock exchange announcement dated 3 July 2017 in which Targovax ASA (the "Company") announced the commencement of the subscription period of the rights issue by the Company of 2,000,000 new [...]

CrownBio démontre des progrès scientifiques dans les maladies métaboliques avec un modèle translationnel validé et amélioré pour la découverte de médicaments contre l'obésité et le diabète de type 2

07/07/2017 - 10:52

SANTA CLARA, Californie, le 7 juillet 2017 (GLOBE NEWSWIRE) - Crown Bioscience , une filiale en propriété exclusive de Crown Bioscience International (TWSE : symbole boursier 6554) et une société mondiale de services de [...]

Changes in Oriola's Group Management Team

07/07/2017 - 10:00

Oriola Corporation Stock Exchange Release 7 July 2017 at 11.00 Changes in Oriola's Group Management Team Page Content Anders Torell (b. 1967), M.Sc.Eng., has been appointed Vice President of Oriola's Consumer Business [...]

Curetis To Attend Key Investor and Scientific Conferences In The Third Quarter 2017

07/07/2017 - 08:27

Curetis To Attend Key Investor and Scientific Conferences In The Third Quarter 2017 Amsterdam, the Netherlands, and Holzgerlingen, Germany, July 7, 2017 -- Curetis N.V. (the " Company " and, together with Curetis GmbH [...]

Zealand Pharma A/S convenes an extraordinary general meeting 2017

07/07/2017 - 07:55

Zealand Pharma A/S indkalder til ekstraordinær generalforsamling 2017 Zealand Pharma A/S convenes an extraordinary general meeting 2017 Indkaldelse til ekstraordinær generalforsamling i Zealand Pharma A/S (CVR-nr. 20 04 [...]

argenx presents full data from ARGX-111 Phase Ib study in patients with advanced cancers over-expressing the MET protein at Best of ASCO Asia 2017 (Singapore)

07/07/2017 - 07:00

July 7, 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment [...]

Zealand Pharma files registration statement for proposed initial public offering of ADSs in the U.S.

06/07/2017 - 23:17

Company announcement - No. 25/2017 Zealand Pharma files registration statement for proposed initial public offering of ADSs in the U.S. Zealand has today filed a registration statement for the proposed initial public [...]

VALNEVA : Déclaration d'actions et de droits de vote - Juin 2017

06/07/2017 - 18:00

VALNEVA Déclaration d'actions et de droits de vote - JUIN 2017 Dénomination sociale : VALNEVA Adresse du siège social : World Trade Center Lyon, Tour Oxygène, 10-12 Boulevard Marius Vivier Merle, 69003 Lyon Marché [...]

VALNEVA : Bilan semestriel du contrat de liquidité

06/07/2017 - 18:00

Paris, le 6 juillet 2017 Bilan semestriel du contrat de liquidité VALNEVA contracté avec NATIXIS Au titre du contrat de liquidité confié à NATIXIS portant sur les actions de la société VALNEVA, à la date du 30 juin 2017 [...]

Weifa ASA: Invitation to presentation of Weifa's Q2 2017 results, Thursday 13 July 2017

06/07/2017 - 15:40

Oslo, 6 July 2017 Weifa ASA (OSE: WEIFA), Norway's leading consumer health company, will release its second quarter and first half 2017 results on Thursday 13 July 2017. The results will be presented by Weifa's CEO [...]

CrownBio Demonstrates Scientific Advancements in Metabolic Disease with a validated and improved translatable model for obesity and Type 2 Diabetes drug discovery

06/07/2017 - 14:00

SANTA CLARA, Calif., July 06, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience , a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company [...]

ProMIS(TM) Neurosciences' Sponsored Research Agreement with University of British Columbia Receives Matching Grant from Canadian Institutes of Health Research

06/07/2017 - 13:30

TORONTO and CAMBRIDGE, Mass., July 06, 2017 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today [...]

Shire submits investigational New Drug Application to FDA for Gene Therapy candidate SHP654 for treatment of Hemophilia A

06/07/2017 - 13:00

Shire submits investigational New Drug Application to FDA for Gene Therapy candidate SHP654 for treatment of Hemophilia A SHP654 aims to deliver sustained protection against bleeds for patients with hemophilia A [...]

Targovax ASA: Registration of share capital increase following the private placement

06/07/2017 - 11:06

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE [...]